Literature DB >> 16342845

Management of active tuberculosis.

Beth Potter1, Kirsten Rindfleisch, Connie K Kraus.   

Abstract

Although the overall incidence of tuberculosis has been declining in the United States, it remains an important public health concern, particularly among immigrants, homeless persons, and persons infected with human immunodeficiency virus. Patients who present with symptoms of active tuberculosis (e.g., cough, weight loss, or malaise with known exposure to the disease) should be evaluated. Three induced sputum samples for acid-fast bacillus smear and culture should be obtained from patients with findings of tuberculosis or suspicion for active disease. If the patient has manifestations of extrapulmonary tuberculosis, smears and cultures should be obtained from these sites. Most patients with active tuberculosis should be treated initially with isoniazid, rifampin, pyrazinamide, and ethambutol for eight weeks, followed by 18 weeks of treatment with isoniazid and rifampin if needed. Repeat cultures should be performed after the initial eight-week treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16342845

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  4 in total

1.  Structure and inhibition of human diamine oxidase.

Authors:  Aaron P McGrath; Kimberly M Hilmer; Charles A Collyer; Eric M Shepard; Bradley O Elmore; Doreen E Brown; David M Dooley; J Mitchell Guss
Journal:  Biochemistry       Date:  2009-10-20       Impact factor: 3.162

2.  Knowledge and perceptions of tuberculosis among a sample of urban Aboriginal people.

Authors:  Paul Brassard; Kelly K Anderson; Dick Menzies; Kevin Schwartzman; Mary Ellen Macdonald
Journal:  J Community Health       Date:  2008-08

3.  Tuberculosis infection among homeless persons and caregivers in a high-tuberculosis-prevalence area in Japan: a cross-sectional study.

Authors:  Takahiro Tabuchi; Toshio Takatorige; Yukio Hirayama; Nobuaki Nakata; Shigeyoshi Harihara; Akira Shimouchi; Koshiro Fujita; Hiroko Yoshida; Yoshitaka Tamura; Takayuki Nagai; Tomoshige Matsumoto; Tetsuya Takashima; Hiroyasu Iso
Journal:  BMC Infect Dis       Date:  2011-01-21       Impact factor: 3.090

4.  Isoniazid inhibits the heme-based reactivity of Mycobacterium tuberculosis truncated hemoglobin N.

Authors:  Paolo Ascenzi; Andrea Coletta; Yu Cao; Viviana Trezza; Loris Leboffe; Gabriella Fanali; Mauro Fasano; Alessandra Pesce; Chiara Ciaccio; Stefano Marini; Massimo Coletta
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.